Glucose results tell you about blood sugar. Kidney, lipid, and liver results answer additional questions about your health. A person can have an improving A1C while urine albumin remains elevated, cholesterol-related risk persists, or liver fibrosis needs evaluation. Reading relevant results together helps identify what has improved and what still needs attention.
This guide explains prediabetes and type 2 diabetes tests for nonpregnant adults, including confirmation, conflicting results, and follow-up. For the broader framework for selecting screening, diagnostic, classification, and monitoring tests, start with our Diabetes and Prediabetes Blood Tests guide.
Prediabetes means blood glucose is above the usual range but below the diabetes threshold. It signals increased risk; progression to type 2 diabetes is not inevitable. Type 2 diabetes develops when insulin resistance and insufficient insulin secretion lead to sustained high blood glucose. Both conditions can be present without obvious symptoms.
Risk reflects interacting factors, including family history, age, body composition, physical activity, sleep, medications, and other health conditions. Food choices matter, but one meal or one personal characteristic cannot explain the diagnosis. Learn more in Insulin Resistance and Type 2 Diabetes: Risk, Testing, and Prevention. [1]
The American Diabetes Association recommends screening adults beginning at age 35, with earlier testing for adults with overweight or obesity and additional risk factors. These include a close family history, previous gestational diabetes, high blood pressure, cardiovascular disease, and other features associated with insulin resistance. [2]
Another relevant condition is polyendocrine metabolic ovarian syndrome (PMOS), formerly polycystic ovary syndrome (PCOS). The new name was announced in May 2026; older records and guidelines may still use PCOS. [3]
Symptoms such as increased thirst, frequent urination, blurred vision, or unexplained weight loss warrant timely clinical evaluation, regardless of your age or last screening result.
These tests examine different aspects of glucose regulation. Comparing them can resolve a specific uncertainty, but agreement among all three is not required to diagnose diabetes.
The Hemoglobin A1C test measures the percentage of hemoglobin with glucose attached. It reflects approximately two to three months of glucose exposure, with recent weeks contributing more strongly. Fasting is not required for this test alone. Diagnostic testing should use an NGSP-certified laboratory method. Because it is an average, it can conceal substantial daily highs and lows. It also depends on red blood cells and the measurement method. [4]
A fasting plasma glucose test measures glucose after at least eight hours without caloric intake. It shows what is happening at that collection time. Recent illness, stress, medications, preparation, and sample handling can influence the result. A reassuring fasting value does not exclude an abnormal response to a glucose challenge. [5]
The Glucose Tolerance Test, 2 Specimens (75g) compares fasting glucose with a timed result after a 75-gram glucose drink. For the nonpregnant diagnostic framework in this article, the post-challenge result is measured at two hours. It can reveal impaired glucose tolerance that another test misses. This is a standardized glucose challenge, not a measurement of your response to a usual mixed meal. [5]
Preparing for an OGTT: Follow a mixed eating pattern containing at least 150 grams of carbohydrate daily for the three days before testing, then complete the required overnight fast of at least eight hours. Confirm the collection site's fasting and two-hour sampling protocol before your appointment. Ask how to handle medications and what is allowed during the test; do not change prescribed treatment on your own. [2]
A continuous glucose monitor (CGM) can show glucose patterns and support diabetes management. Current evidence does not support substituting CGM readings for accepted laboratory diagnostic criteria. An unexpected wearable pattern can prompt a clinical discussion and appropriate laboratory testing. [2]
The following thresholds apply to nonpregnant adults. Pregnancy uses different testing pathways. Glucose values are in mg/dL.
| Test | Below the prediabetes range | Prediabetes range | Diabetes range |
|---|---|---|---|
| A1C | Below 5.7% | 5.7%–6.4% | 6.5% or higher |
| Fasting plasma glucose | Below 100 | 100–125 | 126 or higher |
| Two-hour plasma glucose during a 75g OGTT | Below 140 | 140–199 | 200 or higher |
A random plasma glucose of 200 mg/dL or higher with classic hyperglycemic symptoms or a hyperglycemic crisis also meets a diabetes criterion. Without unequivocal hyperglycemia, confirmation requires two abnormal results: the same test repeated or two different accepted tests. The results may come from the same collection or separate collections. [6]
Example: Reliable laboratory A1C results of 6.7% and 6.8% can confirm diabetes even if fasting glucose is below 126 mg/dL. The next questions concern diabetes type, symptoms, and a care plan. Kidney, lipid, and liver tests do not have to be abnormal for diabetes to be present.
Do not average the numbers or dismiss the abnormal result. If one accepted test is in the diabetes range and another is not, clinicians generally repeat the test above its diagnostic threshold and investigate the discrepancy. When A1C is unsuitable for diagnosis, plasma-glucose criteria should guide the assessment. [6]
Shortened red-cell survival, recent blood loss, transfusion, and some treatments can lower A1C independently of glucose. Significant iron deficiency can raise it. Hemoglobin variants can interfere with some assays, and advanced kidney disease can complicate interpretation. The direction and size of the effect depend on the situation. [7]
A Complete Blood Count with Differential and Platelets or Ferritin, Iron and Total Iron Binding Capacity Panel may help investigate anemia or iron deficiency when the history supports testing. Normal results cannot certify that A1C is reliable. Review recent treatment changes, illness, fasting status, and previous trends as well.
Kidney assessment asks whether filtration or the kidney's barrier to protein leakage is affected. These questions remain relevant when blood glucose improves.
Creatinine-based estimated glomerular filtration rate (eGFR), reported with the Comprehensive Metabolic Panel (CMP), estimates filtration. The Albumin Random Urine Test with Creatinine provides the urine albumin-to-creatinine ratio (UACR), which evaluates albumin leakage. A blood chemistry panel does not replace this urine measurement. [20]
In type 2 diabetes, both should be assessed at diagnosis and at least annually thereafter. People with established chronic kidney disease may need more frequent testing. Prediabetes alone does not automatically require the same kidney surveillance schedule; other risk factors and clinical findings guide testing. [8]
| Result pattern | What needs attention? |
|---|---|
| eGFR at least 60 mL/min/1.73 m²; UACR below 30 mg/g | No reduced-filtration or elevated-albumin signal from these two values; continue risk-based follow-up. Other kidney abnormalities remain possible. |
| eGFR at least 60; UACR at least 30 mg/g | Albumin leakage may be present despite preserved filtration. Check temporary influences and whether the elevation persists. |
| eGFR below 60; UACR below 30 mg/g | Reduced filtration can occur without albuminuria. Review prior results, possible acute causes, and persistence. |
| eGFR below 60; UACR at least 30 mg/g | Both dimensions are abnormal. The degree of change, symptoms, and persistence guide urgency and further assessment. |
Common UACR categories are below 30 mg/g, 30–299 mg/g, and 300 mg/g or higher. Risk generally increases as filtration falls and albumin leakage increases. A single result cannot establish the cause or duration of kidney disease. For the full framework, see Kidney Function Tests: eGFR, Creatinine, Cystatin C, uACR, and Urinalysis. [9]
Because urine albumin varies, two of three UACR specimens collected over approximately three to six months should be abnormal before identifying persistent moderately or severely elevated albuminuria. Exercise within the preceding 24 hours, infection, fever, menstruation, heart failure, marked hyperglycemia, and marked hypertension can raise the result independently of persistent kidney damage. [8]
Creatinine-based eGFR can also be influenced by muscle mass, recent meat intake, supplements, medications, hydration, and acute illness. Share that context with the clinician interpreting the results. [9]
Chronic kidney disease requires evidence of kidney abnormalities lasting at least three months. Previous records can help establish duration. A sharp change in filtration, markedly abnormal results, or concerning symptoms may require prompt evaluation; the chronicity requirement is not a reason to delay care. [9]
A Lipid Panel with Ratios measures cholesterol and triglyceride-related markers, including LDL cholesterol, HDL cholesterol, and non-HDL cholesterol. These describe a different aspect of risk from glucose exposure. Triglycerides may improve with better glucose management, but LDL-related risk can remain.
Selected patients may benefit from Apolipoprotein B (ApoB) testing to help assess the burden of atherogenic particles, particularly when the standard lipid results leave an unresolved risk question. It is not required for every person with prediabetes or diabetes. [10]
An A1C at the individualized goal does not mean that cardiovascular prevention is complete. Blood pressure, smoking, kidney disease, prior cardiovascular events, and the lipid profile still matter. Treatment decisions should reflect the overall risk assessment. See the Heart Health Blood Tests guide for a broader explanation. [11]
Type 2 diabetes increases concern for metabolic dysfunction-associated steatotic liver disease (MASLD), in which liver fat occurs alongside cardiometabolic risk factors. Some people develop fibrosis, or liver scarring. Normal ALT and AST do not reliably exclude clinically important fibrosis.
ADA guidance recommends assessing fibrosis risk in adults with type 2 diabetes, and in adults with prediabetes particularly when obesity or other cardiometabolic risk factors are present, even when liver enzymes are normal. The initial assessment commonly uses FIB-4. [12]
FIB-4 is a calculated risk estimate using age, AST, ALT, and platelet count. The FIB-4 Index Liver Health Evaluation (Self Calculation) supplies those laboratory measurements; age must be added and the score calculated separately. A CMP already contains the two enzyme measurements, and a CBC with platelets supplies the platelet count, so review existing results before ordering overlapping panels.
| FIB-4 result or circumstance | Typical clinical interpretation |
|---|---|
| Below 1.3 in adults ages 35–64 | Lower likelihood of advanced fibrosis; reassessment depends on metabolic risk and the clinical picture. |
| 1.3–2.67 in adults ages 35–64 | Further risk assessment is generally appropriate, often with liver stiffness measurement or an additional blood-based test. |
| Above 2.67 | Higher concern for advanced fibrosis; specialist evaluation is generally appropriate. |
| Age 65 or older | An initial threshold around 2.0, rather than 1.3, is commonly used because age itself raises the score. |
| Under age 35 or acutely ill | Accuracy is limited in younger adults; acute illness can distort the inputs. A low score should not override a concerning clinical assessment. |
FIB-4 estimates risk; it does not diagnose MASLD, confirm a fibrosis stage, or identify the cause of abnormal enzymes. Persistent enzyme elevation still needs evaluation, even with a low score. Follow-up may include transient elastography, an imaging-based stiffness measurement, or an Enhanced Liver Fibrosis (ELF) Score when appropriate. [12], [13]
For the detailed pathway, read MASLD Fibrosis Risk: Testing for Silent Liver Scarring Before Symptoms Appear. The Liver Function Tests guide explains how enzyme, protein, and other liver-related results fit together.
Unexpected weight loss, ketosis, rapid progression, or an early need for insulin can prompt reassessment of a presumed type 2 diagnosis. Adult-onset autoimmune diabetes can occur at any body size.
In a clinically selected evaluation, Glutamic Acid Decarboxylase-65 (GAD65) Antibody is often the first antibody test, with IA-2 Antibody and Zinc Transporter 8 Antibody considered when appropriate. C-Peptide, interpreted with a concurrent glucose result and relevant treatment and kidney-function context, can help assess endogenous insulin secretion. No single result should be interpreted in isolation. These are not routine tests for every person with prediabetes. See Adult-Onset Autoimmune Diabetes (LADA): When Type 2 Does Not Fit. [19]
Long-term metformin use can contribute to vitamin B12 deficiency. Periodic Vitamin B12 assessment is appropriate to consider, especially with anemia or peripheral neuropathy. Numbness and tingling should not automatically be attributed to diabetes. [15]
For a borderline result or persistent clinical suspicion, Methylmalonic Acid (MMA) may help investigate deficiency. Kidney impairment can also raise MMA, which makes the kidney results relevant here too. B12 deficiency and diabetic neuropathy can coexist, and absence of anemia does not exclude deficiency. [16] Read the focused Vitamin B12 Deficiency and Autoimmune Gastritis guide for the broader diagnostic discussion.
These examples are illustrative, not diagnoses or treatment instructions. They assume nonpregnant adults and appropriate laboratory collection. The next step depends on symptoms, prior results, medications, and clinical evaluation.
| Result pattern | Possible meaning | Next clinical question |
|---|---|---|
| A. A1C 6.7%, then 6.8% | Two qualifying results can confirm diabetes if the method and red-cell context support reliability. | What diabetes type and care plan fit the person? |
| B. A1C 6.6% and fasting glucose 132 mg/dL from the same collection | Two different accepted criteria are in the diabetes range. | Have preparation, symptoms, and possible interference been reviewed? |
| C. A1C 6.6% with fasting glucose 103 mg/dL | Discordant diagnostic categories. | Does repeat testing confirm the elevated result, and could red-cell or assay factors explain the difference? |
| D. A1C 5.6%, fasting glucose 98 mg/dL, two-hour OGTT 172 mg/dL | The post-challenge value is in the impaired glucose tolerance range. | What prevention and follow-up plan fits the overall risk? |
| E. A1C 6.1% and fasting glucose 114 mg/dL | Both results fall in the prediabetes range. | Which modifiable risks and monitoring intervals deserve attention? |
| F. eGFR 85 mL/min/1.73 m² with UACR 75 mg/g | Preserved filtration with elevated urine albumin. | Are temporary causes present, and is the elevation persistent? |
| G. Type 2 diabetes, mildly elevated ALT, and a high FIB-4 | The degree of enzyme elevation may understate fibrosis risk. | Is second-stage fibrosis assessment or specialist referral appropriate? |
| H. Presumed type 2 diabetes, weight loss, rapidly increasing insulin needs, and positive GAD65 antibodies | Autoimmune diabetes becomes an important possibility. | Does the classification and treatment plan need prompt reassessment? |
| I. Metformin use, neuropathy, enlarged red cells, and low vitamin B12 | Deficiency may contribute to symptoms and blood-count changes. | How should deficiency and other possible causes of neuropathy be evaluated together? |
| J. A1C 8.2% → 7.1% → 6.7%, with improving glucose and triglyceride trends | Several markers suggest improvement. | Is the change sustainable and safe, and are kidney, lipid, and liver follow-up needs being met? |
| K. Improving A1C with rising UACR | Glucose improvement has not resolved the kidney concern. | Does the urine trend persist, and what kidney and blood-pressure evaluation is needed? |
| L. A1C at the individualized goal with elevated LDL cholesterol or ApoB | Residual cardiovascular risk may need attention. | Does the cardiovascular prevention plan address the remaining risk? |
| Situation | Usual approach |
|---|---|
| Screening results below the prediabetes range | Repeat at least every three years, sooner when risk or symptoms change. |
| Prediabetes | Test for diabetes at least annually; individual risk can justify earlier reassessment. |
| An unconfirmed diabetes-range result | Arrange timely confirmation rather than waiting for a routine screening interval. |
| Diabetes with stable glucose management at the individualized goal | Assess glycemic status, commonly with A1C, at least twice yearly. |
| Treatment changes, unstable glucose, or goals not met | Reassess glycemic status more frequently, often about every three months. |
| Type 2 diabetes kidney assessment | At least annual eGFR and UACR; repeat abnormalities and monitor established kidney disease as clinically indicated. |
| Lipid, liver, or nutrient follow-up | Timing depends on baseline findings, treatment changes, symptoms, and the purpose of testing. |
These schedules serve different purposes. A confirmation test, a treatment-response check, and long-term screening do not use the same timeline. A common A1C goal for many nonpregnant adults with diabetes is below 7%, but goals should account for hypoglycemia risk, health status, and personal circumstances. [6], [8], [17]
Laboratory tests can identify abnormal patterns and help track change. They do not provide a complete examination, establish every cause, or replace retinal screening, foot and nerve assessment, blood-pressure measurement, and a medication review. A result within the laboratory reference interval does not automatically exclude disease or meet an individualized treatment goal.
For help reading units, reference intervals, and trends, visit How to Read Lab Results. For the larger testing framework, see The Complete Guide to Lab Tests and Blood Work.
Vomiting, abdominal pain, rapid or deep breathing, confusion, severe dehydration, or inability to keep fluids down can signal a hyperglycemic emergency. Diabetic ketoacidosis can occur without markedly elevated glucose, particularly in people taking SGLT2 inhibitors. A modest glucose reading should not dismiss concerning symptoms. Seek urgent medical care; do not wait for a routine laboratory appointment. [18]
Severe low glucose with seizure, unconsciousness, or inability to self-treat also requires emergency assistance. [17] Our Diabetic Ketoacidosis and Ketone Testing guide explains how emergency evaluations differ from routine monitoring.
This inventory groups the tests discussed above by purpose. It is not a recommendation to order every item. Review recent results and overlapping panel components with your clinician before selecting tests.
Yes. Results can return below the prediabetes range, and sustained lifestyle changes can reduce progression risk. Continued follow-up remains useful because underlying risk can persist. [1]
The best starting test depends on the clinical question, fasting feasibility, and whether A1C is reliable. An accepted glucose test or A1C can begin screening; additional testing should answer a specific question.
Yes. They measure different aspects of glucose regulation. An abnormal post-challenge result deserves interpretation on its own terms, including appropriate confirmation when it is in the diabetes range.
No. Standard prediabetes criteria use A1C or accepted plasma-glucose measurements. Insulin resistance is not established by a universal insulin cutoff, and routine insulin measurement is generally unnecessary for diagnosing type 2 diabetes. [14]
Kidney risk depends on more than today's glucose level. In established type 2 diabetes, kidney screening remains appropriate even when glucose is near goal. With prediabetes, other risk factors help determine whether kidney testing is indicated.
No. Liver enzyme activity and fibrosis are different measurements. Appropriate fibrosis risk assessment can be warranted in type 2 diabetes despite normal enzymes.
Bring your recent results and the specific question you want answered to your clinician. The linked test pages above let you review the relevant measurements and preparation details. Our Direct Access Lab Testing guide explains the ordering approach, while the Diabetes and Prediabetes Blood Tests pillar helps place each test in the larger care pathway.
The goal is a connected interpretation: confirm glucose status appropriately, investigate results that disagree, and keep kidney, cardiovascular, and liver questions visible even when glucose improves.
This article provides general education and does not replace individualized medical assessment. Diagnostic thresholds, monitoring goals, and the choice of additional tests require clinical interpretation.
Originally published: August 2, 2026 | Updated: Seotember 10 2026
\
Glucose screening, confirmation, and monitoring
Kidney and metabolic assessment
Lipids and cardiovascular-risk assessment
Liver enzymes and fibrosis-risk assessment
Blood-count, iron, and vitamin B12 evaluation
Selected diabetes-classification testing
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
